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This article provides an overview of the scientific literature in which chemically sensitive patients
have been directly evaluated. For that purpose, consideration of various case definitions is offered
along with summaries of subjects' demographic profiles, exposure characteristics, and symptom
profiles across studies. Controlled investigations of chemically sensitive subjects without other
organic illnesses are reviewed. To date, psychiatric, personality, cognitive/neurologic,
immunologic, and olfactory studies have been conducted comparing subjects with primary
chemical sensitivity to various control groups. Thus far, the most consistent finding is that
chemically sensitive patients have a higher rate of psychiatric disorders across studies and
relative to diverse comparison groups. However, since these studies are cross-sectional, causality
cannot be implied. Demonstrating the role of low-level chemical exposure in a controlled
environment has yet to be undertaken with this patient group and is crucial to the understanding
of this phenomenon. Environ Health Perspect 105 (Suppl 2):409-415 (1997)
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Background and Introduction
Exposure to chemicals contained in products
such as perfumes, household cleaners, and
petroleum-based products has been consid-
ered safe and often pleasant. However,
reports ofunusual sensitivity and illness in
response to such items have increased. For
example, in the occupational literature,
Schottenfeld and Cullen (1) first described
a group of patients who became ill follow-
ing exposure and who later developed med-
ically unexplained symptoms triggered by
events (e.g., exposure to odors such as per-
fumes) that reminded them of their expo-
sure-related illness. Schottenfeld and
Cullen described this reaction as an anxiety
response, i.e., typical and atypical post-
traumatic stress disorder, rather than a
heightened physiological sensitivity to
chemicals. Several other investigators have
suggested that sensitivity to low-level chem-
ical exposures is the modern expression of
well-known psychiatric disorders such as
anxiety, depression, or somatization (2,3).
A growing debate has arisen between those
who regard chemical sensitivity as a disor-
der mediated by psychiatric factors in a
manner similar to conditioned responses
and those who see it as a genuine physical
susceptibility to low-dose exposures pre-
sumed safe. In 1987, Cullen edited a state
ofthe art review for occupational medicine
on multiple chemical sensitivities (MCS)
in which he suggested a case definition to
promote commonality among cases. This
definition also attempted to distinguish
MCS, at least conceptually, from tradi-
tional occupational disease and psychiatric
illness. The following components were
proposed: initial symptoms acquired in
relation to an identifiable environmental
exposure(s); symptoms that involve more
than one organ system; symptoms that
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recur and abate in response to predictable
stimuli; symptoms elicited by low-level
exposures to chemicals ofdiverse structural
classes; and inability to explain symptoms
by standard tests oforgan-system function.
Decades prior to the recognition of
MCS in the occupational health literature,
clinical ecologists or environmental physi-
cians suggested that exposure to levels of
chemicals most ofthe population tolerates
may produce symptoms and illness in sus-
ceptible individuals (4). However, those
physicians cast a much wider net to
attribute many defined pathologic illnesses
such as cancer, arthritis, and vasculitis to
chemical exposures (5). They invoked the
general adaptation syndrome model of
stress, proposed by Selye (6), to explain
the health effects of chemical exposures.
That is, normally the organism adapts to a
stressor (chemical) even though symptoms
may be triggered. With repeated exposure,
however, the organism's ability to adapt
becomes compromised, leading ultimately
to end-organ failure or disease. Genetic
and psychosocial factors contribute to indi-
vidual susceptibility to illness resulting
from stress or chemical exposures. Hence,
individual differences mediate the ability to
tolerate chemical exposures.
The ecologic conceptualization ofchem-
ical sensitivity suggests that patients classi-
fied by Cullen's criteria would represent
only a highly selective subset ofpatients in
the earliest stages of chemical sensitivity
since, by definition, no standard test of
organ system function can explain symp-
toms. Thus, known organ dysfunction and
traditional disease states are excluded from
MCS as defined byCullen in 1987 (7).
The contrasting paradigms described
above will significantly affect subject selec-
tion and thus alter the scope and interpre-
tation ofresearch investigations into MCS.
In many ways, researchers from these two
perspectives are studying different phe-
nomena. Under the paradigm of clinical
ecology, the question of concern is the
interaction ofindividual susceptibility with
chemical exposures in producing not only
chemical sensitivity but also pathologic ill-
nesses. Sensitivity to chemicals, even ifnot
fully appreciated by the patient, is expected
to precede and contribute to many known
illnesses. In contrast, the traditions of
occupational health and toxicology are ask-
ing whether such a phenomenon as hyper-
sensitivity to low-level chemical exposures
can be documented; and ifso, what are the
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mechanisms and implications for treatment
and policy.
In the investigation ofchemical sensitiv-
ities, it is critical to clarify subject selection
criteria. The purpose of the workshop
reported here was to develop experimental
approaches for testing the relationship
between low-level chemical exposure and
symptomatology among chemically sensi-
tive individuals. In other words, is there a
subset of patients who, when exposed to
levels of chemicals well below accepted
standards tolerated by most individuals, will
exhibit symptomatology that can be quanti-
fied objectively? Patients who have devel-
oped pathologic medical illness such as
rheuthatoid arthritis may also have chemi-
cal sensitivities preceding and concurrent
with their illness. However, including
patients with diverse medical conditions
along with those who have no defined
pathology makes it difficult to develop uni-
form protocols with objective measures that
will apply across subjects. Therefore, at the
outset it may be most fruitful to begin with
a definition of chemical sensitivity that
selects patients who do not have other med-
ical illness (7). In light ofthe need to estab-
lish common ground for discussion, the
following summary of the literature is
focused on investigations ofpatients who
report a symptomatic intolerance for low-
level chemical exposures expressed as symp-
toms reflective ofmultiple organ systems
but who do not have other medical illnesses
that might explain their symptoms. The
primary question addressed in these investi-
gations is whether any psychosocial or bio-
logic variables can be discovered that would
explain these unexpected sensitivities.
Demographic and
Case Characteristics
Table 1 summarizes demographic informa-
tion presented by investigators ofpatients
with chemical sensitivities. Despite discrep-
ancies in case selection criteria, the demo-
graphic profile of the patient groups is
strikingly consistent. The average age is in
the.fourth decade with a ratio ofwomen to
men of approximately 8:2. The average
educational level for subjects is at least
2 years ofcollege.
A subset of investigators provided
specific information about onset ofchemi-
cal sensitivity symptoms for their subjects
(8-10). To regard chemical sensitivity as
acquired suggests that there is a date or
timeperiod ofonset. However, for a signif-
icant subset [39% (8); 38% (10)], onset
was reported as gradual and no specific
event or exposure could be recalled (Table
2). For these patients identifying duration
ofillness becomes difficult. Several investi-
gators summarized the initiating exposure
events reported by the subjects. With the
exception of Simon et al. (9) and Miller
and Mitzel (12), initiating events were
highly varied within and between subject
groups (Table 3). In the Simon et al. study
(9), subjects were recruited from one aero-
space manufacturing workplace in which
worker compensation claims were being
evaluated. Miller and Mitzel (12), in a
questionnaire study, included only subjects
who could recall a specific organophos-
phate exposure or remodeling event after
which chemical sensitivities developed.
Subjects who could not recall one ofthese
events at a specific time were not included.
Table 1. Demographic profiles of MCS study subjects.
The remaining studies selected subjects
from the community or recruited subjects
from physicians who were evaluating or
treating their chemical sensitivities. In these
studies, a subset ofsubjects reported events
other than chemical exposures as precipitat-
ing their sensitivity. For example, Terr
(13), Stewart and Raskin (3) and Black et
al. (2) included subjects who reported such
precipitators as stress, antibiotics, and can-
didiasis. Studies by Terr (13), Simon et al.
(9), and Stewart and Raskin (3) were dom-
inated by subjects involved in litigation
related to exposures. As can be seen from
the exposure situations, no single chemical
or psychosocial situation can be identified
as more prevalent than another for the
onset ofchemical sensitivities. This suggests
that the environment, per se, may not be
Gender %
Study, reference no. No. Agea Female Male Education levela
Stewart and Raskin (3) 85 38 83 17 83% well educated
Doty etal. (8) 18 46.1 ± 11.2 67 33 15.1
Terr(13) 90 39.5 range 20-63 70 30 Not given
Black etal. (2) 26 49.1 ± 13.0 88 15 14.6 +2.6
Simon etal. (9) 13
Staudenmeyer (19) 58 40.2 ± 10.2 71 29 Not Given
Buchwald and Garrity (11) 30 40.8 77 23 14.8
Miller and Mitzel(12) 112 47.7 ± 9.1 79.5 20.5 15.9 ± 3.1
Simon(5) 41 46.4 ±9.5 85 15 14.6 ±2.7
Fiedler etal. (10) 23 42.9 ±9.5 83 17 14.6 ±2.5
aValues given as mean ± SD.
Table 2. Illness profile ofchemical sensitivity subjects.
Initiating Duration of
chemical exposure illness, years Multiple organ systems
Study, reference no. No. % oftotal Mean ±SD No. % oftotal
Stewart and Raskin (3) 12 (67) 2 ± 1.4 Not given
Doty etal. (8) 11 (61) 15.6 ±6.3 16 (88.9)
Terr(13) goa Not given 62 (69)
Black et al. (2) 20 (77) Not given (100)
Simon et al. (9) 13 (100) Not given Not given
Millerand Mitzel (12) 112 (100) 7.7 (100)
Fiedler etal. (10) 37 (62) 4.5± 5.2 (100)
"Work-related cause forall patients.
Table 3. Chemical and other exposures precipitating illness.
Study, reference no. Source of exposure
Stewart and Raskin (3) Insecticide, fumes, food additives, candidiasis, antibiotics
Terr(13) 59 overlapping exposures: organic solvents, pesticides, food, dust, stress
Simon et al. (9) One exposure of new composite plastic: phenol,formaldehyde, MEK
Black et al. (2) 5 exposure categories: fumes atwork/home, pesticides, oral contraceptive/
pregnancy, stress, antibiotics
Meggs and Cleveland (23) Organophosphates, volatile organic compounds, lead solder, epoxy resins
Miller and Mitzel (12) 2 exposure categories: organophosphate, remodeling
Fiedler et al. (10) Chemicals (solvents, paint, spray mount, pesticides), carpet/carpet adhesive,
indoorair, medication
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the only significant risk factor. Rather, an
interaction between individual difference
variables and an exposure may produce the
risk for symptomatic chemical sensitivities.
Unlike the majority of studies cited
above, subjects in a study by Simon et al.
(9) were identified from worker's compen-
sation cases following an outbreak ofillness
among a group of plastics workers from
the aerospace industry. Therefore, it was
assumed that these workers (n= 13) all had
a similar initiating exposure. The authors
reported that complaints of symptoms
occurred in response to the introduction of
a new composite plastic material into the
manufacturing process. The principal com-
ponents ofthis material were phenol, form-
aldehyde, and methyl ethyl ketone (MEK).
Exposure measurements did not find levels
that approached established thresholds.
Explicit in the varying definitions of
chemical sensitivities is the concept that
multiple chemicals at low levels produce
symptoms. Kipen et al. (14), using a mod-
ified version ofthe Randolph environmen-
tal questionnaire, found that chemically
sensitive subjects reported significantly
more substances that made them ill than
did either healthy or sick controls (Figure
1). Women reported more substances than
men, independent ofhealth status.
While most investigators imply that
chemically sensitive patients have symptoms
representative of multiple physiologic sys-
tems, not all reported on the organ systems
or symptoms. Table 4 gives a sample ofthe
percentage ofsubjects reporting symptoms
in each organ system (2,8,10). Across
studies, symptoms were most prevalent in
the central nervous (neurologic, psychiatric),
respiratory, and gastrointestinal systems.
However, to date no coherent pattern of
symptoms distinguishes chemical sensitivity.
Preliminary studies show neurologic, cogni-
tive, and emotional symptoms are the best
discriminator between MCS and normals.
Psychiatric Disorders
Since chemical sensitivity does not readily
fit existing paradigms for the relationship
between exposure and symptoms, the psy-
chiatric status ofpatients has been investi-
gated more frequently than that of any of
the organ systems. The Axis I psychiatric
disorders most prevalent among the MCS
patients evaluated are the affective and anx-
iety disorders (Table 5). With the exception
ofStewart and Raskin (3), no investigators
have reported current or previous psychoses
among MCS patients, although we and
others intentionally excluded such subjects.
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Figure 1. Symptomatic substance scores, by diagnostic group. Box and whisker plots of symptomatic scores are
shown for each diagnostic group. Patients with MCS and those with asthma had scores that were significantly
elevated over all others although a number of positive scores occurred in all groups. The lower boundary of each
box represents the 25th percentile, the upper boundary represents the 75th percentile, and horizontal lines repre-
sent medians. *, group mean; o, group outliner; x, extreme value for group; -------, cutoff scorefor a positive test.
Table 4. Symptom profile of chemical sensitivities.
Percent of subjects reporting symptoms
Study, reference no. CNS Respiratory Gastrointestinal Cardiovascular Endocrine
Doty et al. (8) 88.9 66.7 66.7 27.8 22.2
Black et al. (2), Neuro = 38 58.0 12.0 Not given Not given
initial symptoms Psych = 27
Fiedler et al., 91.0 83.0 83.0 83.0 Not given
unpublished data
CNS, central nervous system.
Substance abuse was also rare. Diagnosing
somatization disorder was problematic
since many symptoms were attributed to
chemical sensitivities. Therefore, the per-
centage ofpatients who can be considered
positive for somatization disorder varies
depending on whether or not MCS was
accepted as an organic explanation for a
physical symptom. Subject selection crite-
ria may also have significantly impacted the
outcome on measures ofpsychiatric disor-
ders. For example, Fiedler et al. (10) found
a significantly higher rate ofpsychiatric dis-
orders among patients who did not have a
date ofonset for their chemical sensitivities
(Table 6). Similarly, Stewart and Raskin
(3) and Simon et al. (9) found the highest
rates of psychiatric disorders relative to
other studies. Patients in these studies were
referred by physicians for psychiatric evalu-
ation (3) or were involved in litigation such
as worker's compensation (9). Therefore,
the referral process may have biased subject
selection toward a higher prevalence of
psychiatric disorder. Studies recruiting sub-
jects based on defined criteria found that
from 56 to 75% (16 and 11 patients,
respectively) did not qualify as having any
current psychiatric disorder. Approximately
50% ofsubjects met criteria for an Axis I
psychiatric disorder at some point in their
lifetime (10,15,16).
The rate ofAxis II personality disorders
has been less frequently evaluated. Black
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Table 5. Psychiatric profile of sensitivity patients.
Affective Anxiety Somatization Personality Substance AnyAxis
disorders disorders Psychoses disorder disorder abuse diagnosis
Study, reference no. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Stewartand Raskin (3) 3 (17) 4 (22) 3 (17) 5 (28) - -
Black et al. (2)
Lifetime-DIS 9 (39) 10 (43) - 0 4 (17) 17 (73.9) 1 (4) 15 (65)
Simon et al. (9)
Current-DIS 12 (92) - - 0 0 -
Pre-existing condition 7 (54) - - 0 Somatic trait=
9 (69)
Simon et al. (15)
Current-DIS 12 (29) 14 (34) - 0 - - - - - - 18 (44)
Pre-existing condition 16 (47) 5 (15) - 0 9 (26) - 16 (47)
Fiedler et al. (10)
Current-DIS 4 (17) - 0 - 0 3 (14) - - - 0 6 (26)
Lifetime-DIS 7 (30) 2 (9) - 0 3 (14) - - - 0 10 (43)
DIS, diagnostic interview schedule.
Table 6. Lifetime psychiatric diagnoses.
Multiple Chemical Chronic
chemical sensitivities fatigue
sensitivities (no onset) syndrome Normals
Diagnosis No. % No. % No. % No. % p
Depression 7/23 (30) 7/13 (54) 12/18 (67) 11 2/18 0.003
Anxiety 2/23 (9) 4/13 (31) 5/18 (28) 1/18 (6) 0.11
Prescription drug abuse (0) (0) 2/18 (11) - (0) 0.15
Bulimia (0) 1/13 (8) - (0) (0) 0.18
Somatization disorder 3/22 (14) 1/10 (10) 2/17 (12) (0) 0.37
Total lifetime psychiatric 10/23 (43) 9/13 (69) 13/18 (72) 2/18 (11) 0.004
diagnoses
et al. (16) reported that 75% ofhis sample
met the criteria for a personality disorder
based on a structured interview. Several
studies have used questionnaires to evaluate
traits associated with somatic symptoms.
For example, Fiedler et al. (10) reported
Minnesota Multiphasic Personality
Inventory (MMPI-2) group data consistent
with somatoform disorders (Figure 2).
Other studies using the Symptom Checklist-
90, a list of 90 symptoms associated with
psychiatric disorders, revealed significantly
higher rates ofdepression (15,16), somati-
zation (9,15,16), and anxiety (16) [phobic
anxiety; Simon et al. (15)] than control
subjects. Several studies have found sig-
nificant differences from controls on the
Whitely Index, an illness behavior ques-
tionnaire (9,16), and on the Barsky
Amplification Scale, a scale associated with
somatic symptoms (9). In composite, MCS
subjects relative to controls tend to report a
higher number ofphysical symptoms and
score higher on scales that reflect concerns
with somatic sensations. Preliminary data
from our current study also support sensi-
tivity in response to the physical sensations
ofanxiety (Figure 3).
Regardless of the control groups
chosen, as a group chemically sensitive sub-
jects have significantly more psychopathol-
ogy. A portion of this pathology may be
explained by the higher prevalence of
somatic symptoms, which most subjects
associate with sensitivities to chemicals.
However, Staudenmayer et al. (17)
reported a significantly higher rate ofphys-
ical and sexual abuse among universal reac-
tors. Universal reactors were identified
based solely on the attribution of symp-
toms to multiple chemicals and were com-
pared to a group ofpatients with multiple
chronic symptoms accompanied by an Axis
I psychiatric disorder. Unlike all other
cross-sectional studies ofchemically sensi-
tive subjects, Staudenmayer et al. reported
on a group ofsubjects who were in ongo-
ing psychotherapy. Therefore, the context
in which subjects were evaluated and the
nonspecific case criteria may have biased
subject selection toward a more psycho-
logic explanation for symptoms. On the
other hand, investigators such as Bell et al.
(18) suggest that chemical sensitivities may
arise from an interaction ofpsychologic
stress and chemical exposures. Subjects
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Figure 2. MMPI-2 mean t-scores. MMPI, clinical scale
names: HS, hypochondriasis; D, depression; HY, conver-
sion hysteria; PD, psychopathic deviate; MF, masculin-
ity/femininity; PA, paranoia; PT, psychasthenia; SC,
schizophrenia; MA, hypomania; SI, social introversion.
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Figure 3. Personality variables. Controls are signifi-
cantly different from MCS on all measures. Mean ±
SD; n=23; control n= 13.
studied by Staudenmayer et al. (17) may
represent this complex interaction.
In spite of the elevated rate of psy-
chopathology among groups ofchemically
sensitive subjects, a significant percentage
ofpatients do not meet criteria for any cur-
rent or lifetime psychiatric diagnosis. The
variability in psychiatric status among sub-
jects reporting chemical sensitivities sug-
gests that current and previous psychiatric
status will be an important covariate in the
studyofchemical sensitivities.
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Table 7. Neuropsychologic results of chemical sensitivity.
Visual Visuomotor Mental
Study, reference no. Attention Verbal memory memory speed flexibility
Simon (15) NS Reyauditory, post NS NS NS
distraction trial
Logical memory, immediate
Fiedler etal. (10) NS NS Continuous visual NS NS
memorytest,
false alarms
NS, not significant.
Neuropsychologic
Evaluation
To date, two controlled studies have
appeared in which a standardized neuropsy-
chologic evaluation was reported (Table 7).
Neither study reported neuropsychologic
deficits that could be regarded as significant
after taking into account multiple compar-
isons. Simon et al. (15) reported significant
differences on some measures ofverbal
memory but they were not significant after
adjusting for indices ofpsychologic distress.
Fiedler et al. (10) reported significant
reduction in performance on one aspect of
a visual memory task. However, no differ-
ences were seen on other tasks ofvisual
memory. Thus, despite numerous cognitive
complaints, neuropsychologic testing does
not substantiate cognitive deficits when
MCS patients are evaluatedwithout control
ofthe exposure condition.
Neurophysiology of MCS
Few controlled studies have been conducted
in which neurophysiologic measures such
as electroencephalograms (EEG), single
photon emission controlled tomography
(SPECT), and positron emission tomogra-
phy (PET) have been used to evaluate MCS.
In one controlled study, Staudenmayer and
Selner (19) reported that more chemically
sensitive ("universal reactors") and psycho-
logic subjects were classified as having
higher EEG 5-activity during relaxation
than controls. Chemically sensitive subjects
also had higher levels ofelectromylogram
(EMG) scalp activity than either normal or
psychologic subjects. No differences were
observed between the groups for peripheral
temperature or skin resistance while relax-
ing. The authors report these findings in
support ofthe psychosomatic-hypothesis of
intolerance to environmental chemicals.
Both the psychologic and MCS groups
included a wide range ofpsychologic disor-
der (e.g., multiple personality disorder,
depression, panic). The authors reported
that 50% of the MCS group, who were
willing to accept psychologic intervention,
had various psychiatric diagnoses, but the
diagnoses were not given. This information
suggests that the only difference between
the psychologic and the MCS groups was
the attribution of illness to chemicals or
environmental exposures. Thus, the simi-
larities found between the groups were
not surprising.
While other investigators, e.g., Rea
(20), have reported the use ofSPECT and
PET for evaluation ofchemically sensitive
patients, no controlled studies have yet
appeared in the literature.
Controlled Challenges
Environmental physicians or clinical
ecologists and Selner and Staudenmayer
(21) have reported controlled challenge
studies ofchemically sensitive or environ-
mentally allergic patients. These investiga-
tors use the word control to describe the
use ofmasking and placebos. However, no
study has appeared in the literature in
which normal controls, matched on appro-
priate demographic variables, have also
been challenged or exposed under the iden-
tical protocol. Such controlled studies are
sorely needed and their design is the subject
ofthe present workshop.
Nasal Pathology
and Olfaction
MCS patients often report heightened
odor sensitivity (10). Researchers have
conceptualized that this sensitivity would
be expressed in reduced odor threshold.
Doty et al. (8) found no significant differ-
ences between MCS and age and sex
matched normal controls in their ability to
detect phenyl ethyl alcohol (PEA) or MEK.
Similarly, in standard odor-detection test-
ing, Fiedler et al. (22) also found no signif-
icant difference between normal controls
and MCS subjects in thresholds for PEA or
pyridine (PYR). At suprathreshold concen-
trations ofPEA, MCS subjects reported sig-
nificantly more trigeminal symptoms (e.g.,
burning, stinging) and rated PEA as more
unpleasant and unsafe than did normals.
These differences between MCS and
normals were not observed for PYR, a
known unpleasant, trigeminal stimulant.
Fiedler et al. (10) also found no differences
in performance on the University of
Pennsylvania Smell Identification Test, a
multiple-choice test that assesses the
ability to identify 40 odors.
With regard to nasal pathology, Doty
et al. (8) found that relative to controls,
MCS had an overall increased resistance
before and after threshold testing. Both
MCS and controls also had increased nasal
resistance following threshold testing for
MEK. Meggs et al. (23), in an uncon-
trolled study, reported that 100% (n= 10)
ofthe MCS patients evaluated had abnor-
mal rhinolaryngoscopic findings including
edema, excessive mucous, and cobblestone
appearance ofposterior pharynx and base
ofthe tongue. Kehrl et al. (personal com-
munication) in another uncontrolled study
reported frequent nasal pathology in their
MCS subjects.These findings suggest that
MCS subjects do not necessarily detect
odors at lower concentration, but they may
respond more markedly with symptoms
once odors are detected. How this relates
to observations ofnasal pathology remains
to be explored, although altered breathing
patterns and neurogenic inflammation
have been suggested. The rate of nasal
pathology, however, must be evaluated
relative toappropriate controls.
Immune Function
A number of authors have described
immunologic laboratory abnormalities
in chemically sensitive individuals. All
but one are case series or cross-sectional
studies without control of immediately
preceding exposures or careful concurrent,
blind testing ofcontrols. Elevated immu-
noglobulin levels have been reported
(4,24,25). Antichemical (e.g., formalde-
hyde) antibodies have been reported
(26-28), as have elevated levels ofautoan-
tibodies (29). Changes in lymphocyte sub-
sets have been reported (25-30). The
preliminary description of T-cell subset
abnormalities reported by Kipen et al.
(25), have not been confirmed with testing
ofincreased numbers ofpatients and inclu-
sion ofhealthy controls (31). Elevated fre-
quencies ofactivated lymphocytes are also
described (27-29). Terr published on a
case series of 50 worker's compensation
patients and reported no abnormality of
immunoglobulin, B-cell, and T-cell subset
levels (13). Pathologicinflammatorychanges
in the nose have also been described (32),
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and neurogenic inflammatory processes in
the nose have been proposed as a patho-
genic mechanism for MCS (33). Simon et
al. (15) published the one carefully con-
trolled and laboratory blinded case compar-
ison study of subjects with chemical
sensitivity (Table 8). Compared to subjects
with musculoskeletal problems, tests for
four autoantibodies, B-cells, and T-cell sub-
sets showed no significant differences
between the two groups. Tests for one
autoantibody and two tests ofimmune cell
activation (TAl cell percentage and inter-
leukin-1 [IL-1] generation) showed higher
levels in the musculoskeletal group. Many
values for individuals in both groups were
abnormal according to laboratory reference
ranges. Subsequent correspondence criti-
cized the reported methods for both the
antibody determinations and the determi-
nation of lymphocyte markers (34).
Subsequently, the authors ofthis negative
study disclosed that on a limited number of
split samples, the reliability ofthe labora-
tory was little better than chance (35). It
appears that the methods used in this study
were similar to methods used in many of
the positive studies referenced above. Thus,
while immunologic abnormalities have
been reported in chemically sensitive indi-
viduals, they have not been rigorously con-
firmed. Methodologic issues with respect to
subject and control selection, laboratory
blinding, and technique cloud our ability to
be confident about the presence or absence
of immunologic abnormalities in chemi-
cally sensitive individuals. Even ifthe types
of immunologic changes reported above
were confirmed, their role in advancing
understanding ofthe origin or mechanisms
of chemical sensitivity symptoms is not
clear. The role of a psychoneuroimmuno-
logic approach, including experimental par-
adigms for understanding the interactions
among behavior, symptoms, and immu-
nity, particularly with respect to controlled
challenge testing, awaits explication.
Summary and Conclusions
Controversy has surrounded the process for
selecting or distinguishing patients who
Table 8. Comparison of immunologic studies in patients with multiple chemical sensitivity and controls with mus-
culoskeletal injury.
Cases Controls 95% Clafor
Immunologic study (n=41) (n= 34) difference p-Value
Positive testfor autoantibodies, n(%)
Antismooth muscle 20 (49) 16 (47) (-0.22 to 0.24) >0.2
Antiparietal cell 4(10) 4 (12) (-0.16 to 0.12) >0.2
Antibrush border 5 (12) 11(32) (-0.02 to-0.40) 0.03
Antimitochondria 1(2) 0 (0) (-0.06 to 0.02) >0.2
Antinuclear 4(10) 2 (6) (-0.04to 0.22) >0.2
Any positive 26 (63) 23(68) (-0.28 to 0.14) >0.2
Cellular studies, +SD
Lymphocyte count, x 103/liter 2580 (±546) 2450 (±778) (-171 to 431) >0.2
B-cells, %(+SD) 6.4(4.1) 7.4(6.3) (-1.4to 3.8) >0.2
T-cells, % (+ SD) 69.8 (±9.7) 67.4 (±7.9) (-1.6 to 6.4) >0.2
CD4+ helper cells, % (± SD) 49.4 (+9.2) 46.1 (+7.1) (-0.5 to 7.1) 0.1
CD8+ suppressorcells, % (± SD) 23.2 (+7.7) 22.5 (+ 7.4) (-2.8 to 4.2) >0.2
Interleukin-2+ cells, % (± SD) 2.1 (+2.0) 2.1 (+2.2) NAb >0.2b
TA1+ cells, % (± SD) 6.5 (+ 5.5) 13.0 (+ 10.4) NAb 0.008b
Interleukin-1 generation 3.94(± 5.02) 7.72 (± 6.09) NAb 0.003b
"Confidence Interval given in same units as original measure (proportions for serologic measures, percentages for
lymphocyte subsets). bSkewed distribution requires use of Eilcoxon test; confidence interval not calculated. [From
Simon et al. (15)].
have chemical sensitivity. That is, investi-
gators and clinicians such as Rea (36) and
Ross (37) include patients with diverse
medical conditions as among those suffer-
ing from chemical sensitivities. Thus, their
patient groups are highly heterogeneous
while more recent investigators, using
Cullen's definition (7), have attempted to
reduce this hetergeneity by excluding other
medical illnesses (10,15,38). Under-
standing the characteristics of the subjects
under study is crucial to understanding the
phenomenon of chemical sensitivity.
Therefore, in future studies investigators
may want to include patients with other
diagnoses; subjects should be stratified by
diagnostic category and analyzed distinctly
from subjects whose primary clinical char-
acteristic is sensitivity to low-level chemical
exposure. Cross-sectional comparisons of
MCS subjects have not revealed any consis-
tent cognitive or immunologic pathology
among patients whose primary clinical
characterization is chemical sensitivity.
Even among this potentially more homo-
geneous group, however, subjects suffer
from a range of recognized psychiatric
disorders, including depression and
anxiety. In fact, the most consistent finding
among studies to date is that of a higher
rate of any psychiatric disorder. Since no
prospective studies have yet been under-
taken, causality cannot be implied from
these findings. Case definitions such as the
one suggested by Cullen (7) may offer a
false sense ofhomogeneity among patients.
That is, at this stage ofour understanding,
it remains important to look carefully at
individual data from subjects, since they
may tell us more about the manifestations
of this disorder than group comparisons
when the groups are by necessity poorly
defined. Finally, the crucial point that has
yet to be addressed is the relationship
between low-level chemical exposures and
symptoms/objective illness reported by
chemically sensitive patients. Whatever the
causality, demonstrating a relationship
between chemical exposure at the levels
reported clinically and symptoms in a care-
fully defined set ofpatients is a necessary
first step in determining whether chemical
sensitivity represents an illness that requires
a new model such as that described by
Miller (39).
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